(Q38364647)

2 September 2017

1 reference

title

Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer (English)

1 reference

2 September 2017

1 reference

1 reference

1

Fred Saad

1 reference

2 September 2017

Kurt Miller

2

1 reference

2 September 2017

language of work or name

English

0 references

publication date

20 February 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

85

1 reference

2 September 2017

issue

5

1 reference

2 September 2017

page(s)

976-986

1 reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Abiraterone and increased survival in metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Increased survival with enzalutamide in prostate cancer after chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Alpha emitter radium-223 and survival in metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Abiraterone in metastatic prostate cancer without previous chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Enzalutamide in metastatic prostate cancer before chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Prostate cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Emerging roles of human prostatic Acid phosphatase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Mechanisms of action of tasquinimod on the tumour microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Immunotherapy earns its spot in the ranks of cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Visceral disease in castration-resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

A near miss for prostate cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Recent developments in treatments targeting castration-resistant prostate cancer bone metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.12.029

10.1016/J.UROLOGY.2014.12.029

7 January 2021

Identifiers

DOI

1 reference

2 September 2017

1 reference